Skip to main content

Advertisement

Table 1 Clinicopathological characteristics of 90 HER2-negative metastatic breast cancer patients with detectable CTCs in the peripheral blood samples at baseline

From: The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer

Characteristic Number of patients (%)
Age (years)
 < 40 9 (10.0)
 ≥ 40 to < 60 64 (71.1)
 ≥ 60 17 (18.9)
Menstrual status
 Premenopausal 31 (34.4)
 Menopausal 59 (65.6)
ER status
 Positive 71 (78.9)
 Negative 19 (21.1)
PR status
 Positive 66 (73.3)
 Negative 24 (26.7)
HR status
 Positive 74 (82.2)
 Negative 16 (17.8)
Disease-free survival (months)
 ≤ 12 18 (20.0)
 > 12 to ≤ 24 9 (10.0)
 > 24 to ≤ 60 34 (37.8)
 > 60 29 (32.2)
Number of metastases
 Single 4 (4.4)
 Multiple 86 (95.6)
Position of metastatic site
 Non-visceral 31 (34.4)
 Visceral 59 (65.6)
Previous endocrinotherapy (after confirmed tumor relapse)
 None 71 (78.9)
 First-line 15 (16.7)
 Second-line or more 4 (4.4)
  1. CTCs circulating tumor cells, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progestrone receptor, HR hormone receptor